Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Glyburide

FDA-approved product (tablet, oral), marketed as Diabeta, Glyburide, Glyburide (Micronized) and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Glyburide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas
FDA pharmacologic class
Sulfonylurea FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Glyburide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Glyburide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?

    NCT01215331 · start 2010-08

    Registered record
    Registry ID
    NCT01215331
    Conditions
    Gestational Diabetes Mellitus
    Interventions
    Insulin; Metformin, glyburide and insulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2016-05
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Diabetes Mellitus
    InterventionInsulin; Metformin, glyburide and insulin
    PhasePhase 3
    Registry statusCompleted

  • Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D

    NCT02607410 · start 2010-01

    Registered record
    Registry ID
    NCT02607410
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    sitagliptin; NPH insulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2014-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Interventionsitagliptin; NPH insulin
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

    NCT01357135 · start 2009-07-15

    Registered record
    Registry ID
    NCT01357135
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Metformin; Sitagliptin; Sulfonylurea; Antihyperglycemic Medication
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-07-15
    Completion
    2013-08-31
    Enrolment
    3,453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionMetformin; Sitagliptin; Sulfonylurea; Antihyperglycemic Medication
    PhaseNot recorded
    Registry statusCompleted

  • Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

    NCT01107717 · start 2009-01

    Registered record
    Registry ID
    NCT01107717
    Conditions
    Diabetes
    Interventions
    metformin\pioglitazone\exenatide; metformin, glyburide and glargine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2023-02-03
    Enrolment
    318

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    Interventionmetformin\pioglitazone\exenatide; metformin, glyburide and glargine
    PhasePhase 4
    Registry statusCompleted

  • Risk of Hypoglycemia in Type 2 Diabetes

    NCT00734669 · start 2008-07

    Registered record
    Registry ID
    NCT00734669
    Conditions
    Type 2 Diabetes
    Interventions
    Glibenclamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-07
    Completion
    2016-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionGlibenclamide
    PhaseNot recorded
    Registry statusCompleted

  • Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM

    NCT00417729 · start 2007-01

    Registered record
    Registry ID
    NCT00417729
    Conditions
    Diabetes Mellitus
    Interventions
    Acarbose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2009-01
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionAcarbose
    PhasePhase 4
    Registry statusCompleted

  • Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

    NCT00935805 · start 2006-07

    Registered record
    Registry ID
    NCT00935805
    Conditions
    Diabetes Mellitus; Arterial Hypertension
    Interventions
    Metformin; Glybenclamide; NPH insulin; Hydrochlorothiazide; Propranolol; Captopril; Amlodipine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2006-07
    Completion
    2012-07
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Arterial Hypertension
    InterventionMetformin; Glybenclamide; NPH insulin; Hydrochlorothiazide +3 more
    PhaseNot recorded
    Registry statusUnknown

  • Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

    NCT00286468 · start 2006-04

    Registered record
    Registry ID
    NCT00286468
    Conditions
    Diabetes Mellitus
    Interventions
    Alogliptin and glyburide; Alogliptin and glyburide; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-06
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionAlogliptin and glyburide; Alogliptin and glyburide; Glyburide
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

    NCT00267683 · start 2005-12

    Registered record
    Registry ID
    NCT00267683
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    insulin aspart; glibenclamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-12
    Completion
    2006-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventioninsulin aspart; glibenclamide
    PhasePhase 3
    Registry statusTerminated

  • GALLANT 4 Tesaglitazar vs. Glibenclamide

    NCT00255541 · start 2004-09

    Registered record
    Registry ID
    NCT00255541
    Conditions
    Type 2 Diabetes
    Interventions
    Tesaglitazar; Glibenclamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-09
    Completion
    2006-12
    Enrolment
    580

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionTesaglitazar; Glibenclamide
    PhasePhase 3
    Registry statusTerminated

  • GALLANT 7 Tesaglitazar Add-on to Sulphonylurea

    NCT00251940 · start 2004-07

    Registered record
    Registry ID
    NCT00251940
    Conditions
    Type 2 Diabetes
    Interventions
    Tesaglitazar 0.5 or 1 mg; Glibenclamide 2.5, 5, 10 or 15 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2006-03
    Enrolment
    555

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionTesaglitazar 0.5 or 1 mg; Glibenclamide 2.5, 5, 10 or 15 mg
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

    NCT00759720 · start 2003-11

    Registered record
    Registry ID
    NCT00759720
    Conditions
    Diabetes Mellitus
    Interventions
    TAK-559 and glyburide; TAK-559 and glyburide; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-11
    Completion
    2004-12
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionTAK-559 and glyburide; TAK-559 and glyburide; Glyburide
    PhasePhase 3
    Registry statusTerminated

  • Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

    NCT00123643 · start 2003-05

    Registered record
    Registry ID
    NCT00123643
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    rosiglitazone; glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-05
    Completion
    2005-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Interventionrosiglitazone; glyburide
    PhasePhase 4
    Registry statusCompleted

  • Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting

    NCT00836472 · start 2003-04

    Registered record
    Registry ID
    NCT00836472
    Conditions
    Healthy
    Interventions
    Glyburide/Metformin 5 mg/500 mg Tablets; Glucovance® 5 mg/500 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-04
    Completion
    2003-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGlyburide/Metformin 5 mg/500 mg Tablets; Glucovance® 5 mg/500 mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia

    NCT00608179 · start 2002-08

    Registered record
    Registry ID
    NCT00608179
    Conditions
    Type 2 Diabetes
    Interventions
    Glimepiride; glyburide; glucose clamp; glucose clamp
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-08
    Completion
    2010-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionGlimepiride; glyburide; glucose clamp; glucose clamp
    PhaseNot applicable
    Registry statusCompleted